BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Emunkitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Emunkitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05238883-2513@assetmemo.bio
DTSTAMP:20261121T005232Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Emunkitug: Phase 1 readout est. (NCT05238883)
DESCRIPTION:Emunkitug\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of HFB200301 as a Single Agent and in Combination With Tislelizumab in 
 Adult Patients With Advanced Solid Tumors\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/emunkit
 ug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5238883
URL:https://assetmemo.bio/drug/emunkitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
